MeSH term
Frequency | Condition_Probility | Female | 216 | 0.0 |
Humans | 934 | 0.0 |
Pregnancy | 4 | 0.0 |
Animals | 262 | 0.0 |
Oligonucleotide Array Sequence Analysis | 12 | 1.0 |
DNA/*biosynthesis | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 23 | 0.0 |
*Genes, p16 | 21 | 21.0 |
Genes, p53 | 12 | 2.0 |
Prognosis | 34 | 0.0 |
Research Support, Non-U.S. Gov't | 648 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Biological Markers | 4 | 0.0 |
Genes, Tumor Suppressor | 17 | 2.0 |
Genes, cdc | 5 | 10.0 |
Oncogenes | 5 | 2.0 |
Telomerase/genetics/metabolism | 2 | 6.0 |
Cell Aging | 6 | 6.0 |
Cell Cycle | 84 | 7.0 |
Genes, p16 | 15 | 15.0 |
Models, Biological | 19 | 0.0 |
Protein p16/*metabolism | 12 | 37.0 |
Retinoblastoma Protein/*metabolism | 31 | 16.0 |
p14ARF Protein/metabolism | 2 | 12.0 |
Active Transport, Cell Nucleus/physiology | 3 | 5.0 |
Cell Cycle/*physiology | 24 | 8.0 |
Cell Cycle Proteins/genetics/*metabolism | 6 | 4.0 |
Cell Line | 91 | 0.0 |
Cell Proliferation | 2 | 1.0 |
Cyclin-Dependent Kinases/metabolism | 94 | 27.0 |
Cyclins/metabolism | 68 | 16.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Phosphorylation | 133 | 1.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 6 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 11 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 282 | 0.0 |
Retinoblastoma Protein/metabolism | 97 | 27.0 |
Signal Transduction/*physiology | 7 | 0.0 |
Transcription Factors/genetics/*metabolism | 7 | 0.0 |
Adenoviridae/genetics | 3 | 0.0 |
Apoptosis | 22 | 1.0 |
Bromodeoxyuridine/pharmacology | 3 | 5.0 |
CDC2-CDC28 Kinases/metabolism | 11 | 25.0 |
Cell Differentiation | 18 | 0.0 |
Cell Line, Tumor | 28 | 0.0 |
Cells, Cultured | 81 | 0.0 |
Cyclin-Dependent Kinases/*physiology | 12 | 25.0 |
Dyes/pharmacology | 2 | 2.0 |
G1 Phase | 72 | 22.0 |
Immunoblotting | 24 | 1.0 |
Immunohistochemistry | 75 | 0.0 |
Ki-67 Antigen/biosynthesis | 3 | 3.0 |
Mice | 148 | 0.0 |
Mice, Knockout | 8 | 0.0 |
Mice, Transgenic | 20 | 0.0 |
Proto-Oncogene Proteins/*physiology | 3 | 1.0 |
RNA, Messenger/metabolism | 17 | 0.0 |
RNA, Small Interfering/metabolism | 4 | 2.0 |
S Phase | 33 | 9.0 |
Time Factors | 49 | 0.0 |
Transgenes | 2 | 0.0 |
Cyclin-Dependent Kinases/*genetics | 48 | 72.0 |
Melanoma/*genetics/pathology | 3 | 11.0 |
*Mutation | 27 | 0.0 |
Prospective Studies | 2 | 0.0 |
*Proto-Oncogene Proteins | 416 | 24.0 |
Skin Neoplasms/*genetics/pathology | 3 | 5.0 |
Adult | 109 | 0.0 |
Aged | 96 | 0.0 |
Brain Neoplasms/*genetics | 11 | 7.0 |
Chromosome Deletion | 8 | 1.0 |
Comparative Study | 74 | 0.0 |
DNA Mutational Analysis | 30 | 0.0 |
DNA, Neoplasm/genetics | 12 | 1.0 |
Glioblastoma/genetics | 3 | 10.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Loss of Heterozygosity/genetics | 2 | 1.0 |
Male | 167 | 0.0 |
Middle Aged | 116 | 0.0 |
Nucleic Acid Hybridization | 13 | 0.0 |
Sarcoma/genetics | 2 | 20.0 |
Blotting, Western | 84 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 6 | 3.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 35 | 25.0 |
*Down-Regulation | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 27 | 3.0 |
Tumor Cells, Cultured | 277 | 1.0 |
Cell Aging/*genetics | 3 | 10.0 |
Cell Cycle Proteins/genetics/metabolism | 4 | 5.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Protein p16/genetics/metabolism | 9 | 34.0 |
Cell Cycle/genetics | 10 | 6.0 |
Cell Division/genetics | 9 | 2.0 |
Cyclin-Dependent Kinases/genetics/*physiology | 4 | 44.0 |
Cyclins/biosynthesis/genetics | 4 | 8.0 |
Genes, Retinoblastoma | 7 | 7.0 |
Protein Binding | 56 | 0.0 |
Protein p16/biosynthesis | 6 | 31.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 2 | 5.0 |
Recombinant Fusion Proteins/physiology | 9 | 3.0 |
*Repressor Proteins | 8 | 0.0 |
Retinoblastoma Protein/*physiology | 7 | 21.0 |
Cyclin D1/*analysis | 3 | 27.0 |
Cyclin-Dependent Kinases/*analysis | 11 | 57.0 |
English Abstract | 26 | 0.0 |
Protein p16/analysis | 5 | 26.0 |
Antineoplastic Agents/*pharmacology | 29 | 2.0 |
Cell Cycle/*drug effects | 40 | 23.0 |
Cyclin D1/metabolism | 32 | 22.0 |
DNA/metabolism | 8 | 0.0 |
Down-Regulation | 19 | 0.0 |
HL-60 Cells | 12 | 2.0 |
Microfilament Proteins/metabolism | 4 | 4.0 |
*Muscle Proteins | 12 | 4.0 |
Up-Regulation | 19 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 9 | 5.0 |
Catechin/analogs & derivatives/*pharmacology | 2 | 40.0 |
Cell Division/*drug effects | 16 | 5.0 |
Drug Screening Assays, Antitumor | 8 | 2.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cyclins/*physiology | 10 | 19.0 |
Precipitin Tests | 40 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Chromosome Aberrations | 12 | 2.0 |
Gene Dosage | 4 | 1.0 |
Gene Expression Profiling | 11 | 1.0 |
Polymerase Chain Reaction | 60 | 0.0 |
Aged, 80 and over | 32 | 0.0 |
Apoptosis/*genetics | 4 | 1.0 |
Case-Control Studies | 4 | 0.0 |
Cyclin-Dependent Kinases/genetics | 33 | 56.0 |
DNA, Neoplasm/analysis | 19 | 2.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Fungal Proteins/genetics | 3 | 1.0 |
*Genes, cdc | 4 | 18.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Transcription Factors/genetics | 6 | 0.0 |
Amino Acid Sequence | 78 | 0.0 |
Base Sequence | 80 | 0.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
*Cell Cycle Proteins | 131 | 10.0 |
Cloning, Molecular | 31 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Molecular Sequence Data | 128 | 0.0 |
Protein Isoforms | 3 | 0.0 |
Sequence Alignment | 9 | 0.0 |
Cell Differentiation/genetics | 8 | 3.0 |
Gene Expression Regulation | 18 | 0.0 |
Aneuploidy | 2 | 1.0 |
Neoplasms/etiology/*genetics/pathology | 2 | 66.0 |
Alleles | 14 | 0.0 |
Blotting, Northern | 22 | 0.0 |
Cell Division | 78 | 1.0 |
Chromatin/metabolism | 4 | 1.0 |
Hela Cells | 24 | 0.0 |
Models, Genetic | 7 | 0.0 |
Promoter Regions (Genetics) | 25 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 30 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Cattle | 8 | 0.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 23 | 37.0 |
Cyclins/genetics/metabolism | 12 | 21.0 |
Enzyme Inhibitors/metabolism | 23 | 11.0 |
Gene Products, tax/*metabolism | 2 | 6.0 |
Human T-lymphotropic virus 1/*metabolism | 2 | 10.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 5 | 4.0 |
Recombinant Fusion Proteins/metabolism | 14 | 0.0 |
Cyclin D1/analysis | 6 | 15.0 |
Cyclin-Dependent Kinases/analysis | 6 | 35.0 |
Multivariate Analysis | 5 | 0.0 |
Proto-Oncogene Proteins/analysis | 2 | 1.0 |
Protein p16/*analysis | 5 | 41.0 |
Codon | 3 | 0.0 |
Esophageal Neoplasms/*genetics/metabolism | 2 | 14.0 |
Exons | 15 | 0.0 |
Gene Deletion | 31 | 1.0 |
*Genes, p53 | 3 | 0.0 |
Homozygote | 18 | 0.0 |
Loss of Heterozygosity | 13 | 1.0 |
Mutation | 48 | 0.0 |
Polymorphism, Genetic | 10 | 0.0 |
Protein p53/biosynthesis | 6 | 4.0 |
Sequence Analysis, DNA | 8 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism | 20 | 50.0 |
Drug Design | 2 | 0.0 |
Cell Cycle Proteins/*biosynthesis | 6 | 13.0 |
Cyclin D1/biosynthesis | 8 | 19.0 |
Cyclin-Dependent Kinases/biosynthesis | 14 | 45.0 |
G1 Phase/*physiology | 13 | 28.0 |
*Nuclear Proteins | 37 | 1.0 |
Proto-Oncogene Proteins/biosynthesis | 4 | 2.0 |
Retinoblastoma Protein/biosynthesis | 5 | 21.0 |
Genetic Predisposition to Disease | 9 | 0.0 |
Germ-Line Mutation | 7 | 1.0 |
Melanoma/*genetics | 31 | 20.0 |
Phenotype | 11 | 0.0 |
Receptors, Corticotropin/genetics | 3 | 25.0 |
Receptors, Melanocortin | 4 | 4.0 |
Risk | 2 | 0.0 |
Skin Neoplasms/*genetics | 15 | 12.0 |
Ultraviolet Rays/adverse effects | 5 | 7.0 |
Analysis of Variance | 2 | 0.0 |
Apoptosis/*drug effects | 14 | 1.0 |
Flow Cytometry | 50 | 0.0 |
Molecular Biology | 3 | 1.0 |
Phosphorylation/drug effects | 25 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 33 | 0.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 2 | 5.0 |
Apoptosis/drug effects | 23 | 3.0 |
Cell Cycle Proteins/metabolism | 18 | 5.0 |
Dose-Response Relationship, Drug | 35 | 0.0 |
Mice, Nude | 16 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
Cyclin-Dependent Kinases/*metabolism | 84 | 32.0 |
CDC2 Protein Kinase/metabolism | 15 | 9.0 |
*CDC2-CDC28 Kinases | 155 | 22.0 |
Cell Survival | 10 | 0.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Cyclin B/metabolism | 4 | 4.0 |
Cyclin D1/*metabolism | 22 | 35.0 |
Cysteine Endopeptidases/metabolism | 3 | 1.0 |
DNA Fragmentation | 7 | 2.0 |
Keratin/metabolism | 3 | 2.0 |
Microscopy, Electron | 3 | 0.0 |
Multienzyme Complexes/metabolism | 3 | 1.0 |
Pancreatic Neoplasms/pathology | 2 | 11.0 |
Proteasome Endopeptidase Complex | 8 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 62 | 7.0 |
Cell Cycle Proteins/*metabolism | 20 | 5.0 |
Cyclins/*metabolism | 59 | 21.0 |
DNA Primers/chemistry | 10 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Thymidine/metabolism | 8 | 2.0 |
Tumor Cells, Cultured/drug effects/metabolism | 4 | 2.0 |
Tumor Suppressor Proteins/*metabolism | 3 | 3.0 |
*Electromagnetic Fields | 2 | 6.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
G1 Phase/physiology | 17 | 23.0 |
Rats | 39 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
S Phase/physiology | 9 | 11.0 |
Amino Acid Motifs | 7 | 0.0 |
Binding Sites | 28 | 0.0 |
Models, Molecular | 16 | 0.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Peptide Mapping | 3 | 0.0 |
Protein Conformation | 8 | 0.0 |
Cercopithecus aethiops | 6 | 0.0 |
Cyclin D1/biosynthesis/genetics | 5 | 26.0 |
DNA Replication | 7 | 1.0 |
Immediate-Early Proteins/genetics/*physiology | 2 | 18.0 |
Adenosine Triphosphate/metabolism | 7 | 1.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
DNA/biosynthesis | 12 | 2.0 |
Liver Neoplasms/*metabolism | 4 | 4.0 |
Protein p53/metabolism | 21 | 3.0 |
Transfection | 58 | 0.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
Cell Cycle/drug effects | 43 | 8.0 |
Cell Division/drug effects | 75 | 2.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Culture Media/pharmacology | 3 | 3.0 |
Cyclins/genetics/*metabolism | 14 | 17.0 |
DNA Fragmentation/drug effects | 2 | 2.0 |
Proliferating Cell Nuclear Antigen/metabolism | 9 | 4.0 |
Protein p53/*genetics | 6 | 3.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 2 | 1.0 |
*Apoptosis | 16 | 1.0 |
Cysteine Proteinase Inhibitors/pharmacology | 3 | 1.0 |
Kinetics | 41 | 0.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 4 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 11 | 1.0 |
Mitogens/pharmacology | 3 | 1.0 |
Prostatic Neoplasms/enzymology/*metabolism/pathology | 2 | 16.0 |
Signal Transduction/drug effects | 8 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Gene Expression | 45 | 0.0 |
Mice, Inbred C57BL | 8 | 0.0 |
Organ Specificity | 6 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Cyclins/biosynthesis | 10 | 10.0 |
Electrophoresis, Polyacrylamide Gel | 16 | 0.0 |
Membrane Potentials/drug effects | 2 | 1.0 |
*Proto-Oncogene Proteins c-bcl-2 | 4 | 0.0 |
Signal Transduction | 30 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 21 | 5.0 |
Family Health | 3 | 0.0 |
Nevus/genetics | 2 | 100.0 |
Age Factors | 8 | 0.0 |
Child | 39 | 0.0 |
Child, Preschool | 28 | 0.0 |
*Cyclin-Dependent Kinases | 32 | 17.0 |
G0 Phase/physiology | 3 | 30.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 3 | 5.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Astrocytoma/*genetics/pathology | 2 | 8.0 |
Brain Neoplasms/*genetics/pathology | 6 | 8.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
Neoplasm Proteins/*genetics | 8 | 0.0 |
Neoplasm Staging | 13 | 0.0 |
Protein p16/genetics | 10 | 11.0 |
Protein p53/genetics | 12 | 7.0 |
Receptor, Epidermal Growth Factor/genetics | 6 | 5.0 |
Tumor Markers, Biological/genetics | 3 | 3.0 |
Cell Transformation, Neoplastic/*genetics | 4 | 2.0 |
*Chromosome Aberrations | 8 | 1.0 |
Cyclin-Dependent Kinases/physiology | 7 | 25.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
Adolescent | 48 | 0.0 |
Cell Cycle Proteins/genetics | 3 | 3.0 |
*Gene Expression Profiling | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 22 | 1.0 |
*Lung Neoplasms | 2 | 8.0 |
Circular Dichroism | 4 | 0.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
*Protein Folding | 2 | 1.0 |
Thermodynamics | 3 | 0.0 |
Cell Cycle/*drug effects/physiology | 4 | 30.0 |
Cyclin E/drug effects/metabolism | 2 | 40.0 |
Cyclins/drug effects/metabolism | 4 | 22.0 |
Protein p16/drug effects/metabolism | 3 | 100.0 |
Retinoblastoma Protein/drug effects/metabolism | 6 | 35.0 |
Tretinoin/*pharmacology | 6 | 1.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 7 | 0.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
Mutagenesis | 11 | 1.0 |
Oncogene Proteins/*metabolism | 9 | 10.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
Substrate Specificity | 10 | 0.0 |
Two-Hybrid System Techniques | 10 | 0.0 |
Gene Silencing | 4 | 1.0 |
Retinoblastoma Protein/*genetics/metabolism | 2 | 28.0 |
Methylation | 2 | 0.0 |
Protein p16/*genetics | 17 | 18.0 |
Sequence Deletion/genetics | 2 | 1.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 3 | 1.0 |
Anticarcinogenic Agents/*pharmacology | 6 | 6.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 3 | 3.0 |
Cell Cycle Proteins/biosynthesis | 2 | 7.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Silymarin/*pharmacology | 5 | 29.0 |
Cell Transformation, Neoplastic/genetics | 6 | 2.0 |
Cyclin-Dependent Kinases/*genetics/metabolism | 7 | 58.0 |
Genes, ras | 3 | 1.0 |
*Germ-Line Mutation | 11 | 2.0 |
Mice, Mutant Strains | 5 | 0.0 |
Breast Neoplasms/*metabolism | 5 | 1.0 |
Estradiol/*analogs & derivatives/pharmacology | 3 | 6.0 |
Tumor Suppressor Proteins/metabolism | 8 | 7.0 |
Genes, p16/*physiology | 3 | 37.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Transcription, Genetic | 24 | 0.0 |
Xeroderma Pigmentosum/*genetics | 2 | 3.0 |
*Apoptosis/drug effects | 2 | 1.0 |
Caspases/metabolism | 8 | 1.0 |
Cell Count | 2 | 0.0 |
Cell Division/drug effects/physiology | 14 | 4.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 17 | 33.0 |
G0 Phase/drug effects | 3 | 20.0 |
G1 Phase/drug effects | 25 | 24.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 8 | 9.0 |
Species Specificity | 3 | 0.0 |
COS Cells | 10 | 0.0 |
Cyclin D1/genetics/metabolism | 8 | 32.0 |
Cyclin-Dependent Kinases/genetics/metabolism | 12 | 42.0 |
DNA, Complementary/genetics | 10 | 0.0 |
In Vitro | 12 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
NIH 3T3 Cells | 4 | 1.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Cell Cycle Proteins/biosynthesis/genetics | 3 | 15.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 2 | 3.0 |
Cell Cycle Proteins/*genetics | 8 | 5.0 |
Tumor Suppressor Proteins/*genetics | 3 | 2.0 |
Chromosomes, Human, Pair 12/*genetics | 5 | 4.0 |
Genetic Markers/genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
Karyotyping | 10 | 0.0 |
Metaphase | 3 | 2.0 |
Retroperitoneal Neoplasms/genetics | 2 | 50.0 |
Gene Expression Regulation, Neoplastic | 43 | 2.0 |
Genes, p53/*genetics | 14 | 4.0 |
Protein p16/biosynthesis/genetics | 4 | 40.0 |
Retinoblastoma Protein/biosynthesis/genetics | 3 | 27.0 |
3T3 Cells | 25 | 1.0 |
Fibroblasts/metabolism | 7 | 0.0 |
Genes, p53/genetics | 6 | 2.0 |
Genes, ras/genetics | 4 | 3.0 |
Point Mutation | 15 | 0.0 |
Protein Biosynthesis | 5 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
Tumor Suppressor Proteins/genetics | 4 | 5.0 |
p14ARF Protein/genetics | 3 | 14.0 |
Apoptosis/*physiology | 7 | 1.0 |
Cell Cycle Proteins/*metabolism/physiology | 2 | 40.0 |
Cyclins/physiology | 12 | 30.0 |
Leukemia, B-Cell, Chronic/metabolism/*pathology | 2 | 25.0 |
DNA, Neoplasm/biosynthesis | 3 | 2.0 |
Genes, Reporter | 10 | 0.0 |
RNA, Messenger/genetics | 18 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Cell Death/drug effects | 4 | 2.0 |
Cyclin-Dependent Kinases/drug effects/metabolism | 5 | 33.0 |
G2 Phase/drug effects | 6 | 12.0 |
In Situ Nick-End Labeling | 6 | 1.0 |
Protein-Serine-Threonine Kinases/drug effects/metabolism | 2 | 11.0 |
Cyclin E/antagonists & inhibitors/metabolism | 3 | 100.0 |
*DNA-Binding Proteins | 27 | 1.0 |
G1 Phase/*drug effects/physiology | 6 | 60.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Transcription Factors/drug effects/*metabolism | 2 | 20.0 |
Enzyme Inhibitors | 9 | 10.0 |
Heterozygote | 4 | 0.0 |
Introns | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 35 | 1.0 |
Antigens, CD95/physiology | 2 | 2.0 |
Enzyme Activation | 26 | 0.0 |
G1 Phase/*drug effects | 30 | 38.0 |
Lung Neoplasms/pathology | 3 | 5.0 |
Proto-Oncogene Proteins/metabolism | 12 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 6 | 1.0 |
Quinazolines/*pharmacology | 2 | 2.0 |
Signal Transduction/physiology | 6 | 0.0 |
Drug Stability | 2 | 0.0 |
Temperature | 2 | 0.0 |
*Cell Transformation, Neoplastic | 5 | 1.0 |
Genotype | 9 | 0.0 |
Protein p16/genetics/*metabolism | 7 | 38.0 |
Drug Interactions | 5 | 0.0 |
Enzyme Activation/drug effects | 15 | 1.0 |
Growth Inhibitors/*pharmacology | 5 | 2.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Germ-Line Mutation/*genetics | 4 | 2.0 |
Neoplasms, Multiple Primary/*genetics | 5 | 12.0 |
Pedigree | 16 | 0.0 |
Endometrial Neoplasms/*metabolism/pathology | 3 | 9.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
Protein-Serine-Threonine Kinases/biosynthesis | 5 | 16.0 |
*Cell Differentiation | 4 | 1.0 |
Cell Nucleus/metabolism | 11 | 0.0 |
Cell-Free System | 2 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Microscopy, Fluorescence | 10 | 0.0 |
Muscle, Skeletal/*cytology | 2 | 12.0 |
Transcription Factors/metabolism | 11 | 0.0 |
Ultraviolet Rays | 6 | 0.0 |
*Chromosomes, Human, Pair 12 | 14 | 5.0 |
Follow-Up Studies | 6 | 0.0 |
Gene Amplification | 31 | 4.0 |
Immunoenzyme Techniques | 15 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 4 | 2.0 |
Osteosarcoma/genetics/*metabolism/pathology | 2 | 100.0 |
Proto-Oncogene Proteins/genetics/metabolism | 3 | 1.0 |
Tumor Markers, Biological/genetics/*metabolism | 2 | 5.0 |
Disease Susceptibility | 3 | 0.0 |
Genetic Screening | 4 | 0.0 |
Italy/epidemiology | 4 | 1.0 |
Linkage (Genetics) | 4 | 0.0 |
Protein p16/*genetics/metabolism | 4 | 20.0 |
Disease Models, Animal | 3 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Neurologic Mutants | 2 | 1.0 |
Epithelial Cells/drug effects | 3 | 9.0 |
*Tumor Suppressor Proteins | 110 | 8.0 |
Cell Separation | 2 | 0.0 |
Ligands | 3 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 2 | 1.0 |
Transcription Factors/*metabolism | 18 | 1.0 |
Blotting, Southern | 25 | 0.0 |
Cyclin-Dependent Kinases/biosynthesis/genetics | 5 | 50.0 |
Gene Expression Regulation, Neoplastic/*genetics | 6 | 3.0 |
Glioblastoma/*genetics | 7 | 10.0 |
In Situ Hybridization | 8 | 0.0 |
Mutation/*genetics | 4 | 0.0 |
Signal Transduction/genetics | 4 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Culture Media, Serum-Free | 9 | 2.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 4 | 0.0 |
Proteins/metabolism | 5 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Mouth Neoplasms/*genetics/pathology | 3 | 16.0 |
Proto-Oncogene Proteins/*genetics | 10 | 1.0 |
Cell Cycle/drug effects/*physiology | 6 | 12.0 |
Cyclins/genetics/physiology | 2 | 22.0 |
Estradiol/pharmacology | 3 | 1.0 |
Cyclins/*biosynthesis/genetics | 6 | 17.0 |
*Gene Expression Regulation | 11 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 5 | 1.0 |
*Proteins | 8 | 1.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Neoplasm Proteins/metabolism | 7 | 1.0 |
Stimulation, Chemical | 2 | 0.0 |
Hydroxyurea/pharmacology | 2 | 3.0 |
Structure-Activity Relationship | 21 | 0.0 |
Tumor Cells, Cultured/drug effects | 9 | 1.0 |
Cell Division/physiology | 15 | 1.0 |
*Protein-Serine-Threonine Kinases | 10 | 1.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Translocation, Genetic | 8 | 1.0 |
Cyclin-Dependent Kinases/genetics/metabolism/*physiology | 2 | 40.0 |
Hyperplasia | 2 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
*Point Mutation | 7 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Breast Neoplasms/metabolism/*pathology | 4 | 4.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Cyclin E/*metabolism | 10 | 25.0 |
Fetal Blood/physiology | 4 | 17.0 |
Macromolecular Substances | 11 | 0.0 |
Neoplasm Proteins/*metabolism | 16 | 3.0 |
Nuclear Proteins/metabolism | 13 | 1.0 |
Phosphoproteins/metabolism | 5 | 0.0 |
Protein Processing, Post-Translational/drug effects | 5 | 4.0 |
Protein-Serine-Threonine Kinases/*metabolism | 37 | 5.0 |
Cell Transformation, Neoplastic | 10 | 1.0 |
Nuclear Proteins/genetics/*metabolism | 5 | 1.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 4 | 4.0 |
Cell Cycle/physiology | 18 | 5.0 |
Proteins/physiology | 2 | 1.0 |
Receptors, Growth Factor/physiology | 2 | 4.0 |
Disease-Free Survival | 6 | 0.0 |
Regression Analysis | 3 | 0.0 |
Survival Rate | 7 | 0.0 |
Tumor Markers, Biological/*metabolism | 5 | 1.0 |
*Chromosome Mapping | 4 | 0.0 |
Chromosomes, Human, Pair 9/*genetics | 7 | 6.0 |
Cyclin D1/genetics | 6 | 9.0 |
Cyclins/genetics | 10 | 6.0 |
DNA Methylation | 12 | 1.0 |
Neoplasm Transplantation | 11 | 0.0 |
Proto-Oncogene Proteins/genetics | 9 | 1.0 |
Survival Analysis | 11 | 0.0 |
Transplantation, Heterologous | 10 | 1.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/genetics/*metabolism | 2 | 40.0 |
Proto-Oncogene Proteins c-myc/genetics/*metabolism | 4 | 9.0 |
Skin Neoplasms/genetics/*metabolism | 2 | 18.0 |
Cell Cycle/genetics/*physiology | 3 | 15.0 |
Protein p53/*metabolism | 8 | 1.0 |
Chi-Square Distribution | 2 | 0.0 |
*Nucleic Acid Hybridization | 4 | 7.0 |
Sarcoma/*genetics/pathology | 2 | 28.0 |
Adenoma/*metabolism/pathology | 2 | 5.0 |
Colonic Neoplasms/*metabolism/pathology | 2 | 5.0 |
Cyclins/analysis | 5 | 11.0 |
*G1 Phase | 13 | 27.0 |
Retinoblastoma Protein/analysis | 10 | 29.0 |
Combined Modality Therapy | 6 | 0.0 |
Genetic Markers | 7 | 0.0 |
Cyclin-Dependent Kinases/*biosynthesis/genetics | 5 | 100.0 |
Protein-Serine-Threonine Kinases/*biosynthesis/genetics | 2 | 8.0 |
Retinoblastoma Protein/physiology | 9 | 26.0 |
*Carrier Proteins | 22 | 3.0 |
Cell Cycle Proteins/genetics/*physiology | 2 | 11.0 |
DNA Damage | 7 | 0.0 |
Protein p16/physiology | 4 | 40.0 |
Protein p53/physiology | 4 | 5.0 |
Adenocarcinoma/*genetics/metabolism | 2 | 5.0 |
Apoptosis/genetics | 2 | 0.0 |
Epithelium/metabolism | 4 | 1.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Stomach/metabolism | 2 | 5.0 |
Carcinoma, Squamous Cell/*pathology | 2 | 2.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 9 | 11.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 9 | 9.0 |
Cyclin E/metabolism | 31 | 26.0 |
Estrogens/*metabolism | 2 | 3.0 |
Crystallography, X-Ray | 11 | 1.0 |
Retinoblastoma Protein/*analysis | 3 | 21.0 |
Conserved Sequence | 4 | 0.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Sequence Homology, Amino Acid | 26 | 0.0 |
Trans-Activators/genetics/*metabolism | 3 | 0.0 |
Astrocytoma/*genetics/metabolism/pathology | 2 | 16.0 |
*Disease Models, Animal | 2 | 0.0 |
Glial Fibrillary Acidic Protein/genetics | 2 | 7.0 |
*DNA Damage | 5 | 0.0 |
Neoplasms/genetics | 3 | 2.0 |
Protein p16/genetics/*physiology | 3 | 60.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Australia | 4 | 2.0 |
Genes, Tumor Suppressor/genetics | 5 | 3.0 |
Gene Expression Regulation/physiology | 3 | 1.0 |
Protein p16/*physiology | 3 | 33.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Cyclin-Dependent Kinases/chemistry/metabolism | 2 | 40.0 |
Carrier Proteins/genetics | 4 | 1.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/genetics | 3 | 50.0 |
Embryo | 2 | 0.0 |
*Enzyme Inhibitors | 15 | 37.0 |
*Gene Expression | 5 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Microtubule-Associated Proteins/genetics | 2 | 5.0 |
*Protein p16 | 21 | 56.0 |
Protein-Serine-Threonine Kinases/genetics | 3 | 2.0 |
*Genes, Retinoblastoma | 14 | 13.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Cohort Studies | 3 | 0.0 |
Disease Progression | 19 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Protein p16/*biosynthesis | 9 | 56.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 2 | 0.0 |
Pyrimidines/*pharmacology | 4 | 6.0 |
Cell Line, Transformed | 19 | 1.0 |
Cell Transformation, Viral | 7 | 2.0 |
Mice, SCID | 3 | 0.0 |
Trans-Activation (Genetics) | 11 | 0.0 |
Breast Neoplasms | 6 | 2.0 |
DNA Replication/drug effects | 3 | 1.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 9 | 18.0 |
Spodoptera | 11 | 3.0 |
Cyclin A/analysis | 3 | 25.0 |
Cyclin E/analysis | 4 | 26.0 |
Lymphatic Metastasis | 4 | 0.0 |
Protein-Serine-Threonine Kinases/*analysis | 3 | 23.0 |
Reference Values | 10 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis/genetics | 2 | 16.0 |
S Phase/drug effects | 10 | 17.0 |
Growth Inhibitors/pharmacology | 5 | 3.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Carcinoma, Hepatocellular/*pathology | 2 | 4.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Gene Therapy | 2 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Lentivirus/genetics | 2 | 6.0 |
Oxidation-Reduction | 2 | 0.0 |
Cyclins/immunology/metabolism | 2 | 100.0 |
Jurkat Cells | 8 | 0.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Cluster Analysis | 3 | 1.0 |
Genes, p16/genetics | 5 | 22.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Phosphoric Monoester Hydrolases/genetics | 7 | 9.0 |
Gene Expression/drug effects | 9 | 1.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
Prostatic Neoplasms/*pathology | 4 | 3.0 |
Genes, p16/*genetics | 14 | 31.0 |
Genes, ras/*genetics | 2 | 2.0 |
Proteins/*genetics | 6 | 0.0 |
p14ARF Protein | 17 | 21.0 |
Catechin/*analogs & derivatives/*pharmacology | 3 | 13.0 |
Cell Cycle/drug effects/physiology | 3 | 5.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Plant Extracts/pharmacology | 2 | 5.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Herpesvirus 1, Human/genetics/*physiology | 2 | 13.0 |
Leupeptins/pharmacology | 2 | 1.0 |
Recombinant Proteins/metabolism | 12 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 2 | 1.0 |
Chromosomes, Human, Pair 9/genetics | 4 | 3.0 |
Diploidy | 5 | 4.0 |
Telomere/metabolism | 3 | 18.0 |
Cyclin-Dependent Kinases/*biosynthesis/genetics/metabolism | 2 | 66.0 |
Infant | 15 | 0.0 |
*Loss of Heterozygosity | 2 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Protein p53/genetics/metabolism | 6 | 6.0 |
Cyclin-Dependent Kinases/analysis/genetics | 2 | 100.0 |
Genes, fos | 2 | 1.0 |
Genes, myc | 6 | 2.0 |
Tumor Markers, Biological/analysis/*genetics | 2 | 9.0 |
Cell Differentiation/drug effects | 10 | 0.0 |
Gene Transfer Techniques | 6 | 1.0 |
Baculoviridae/genetics | 3 | 1.0 |
Consensus Sequence/genetics | 2 | 4.0 |
Mutation/genetics | 5 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 6 | 2.0 |
*Cell Aging | 4 | 7.0 |
Ceramides/*pharmacology | 2 | 10.0 |
Fibroblasts/cytology/drug effects/metabolism | 3 | 5.0 |
Glioblastoma/*genetics/pathology | 4 | 17.0 |
Carrier Proteins/metabolism | 10 | 1.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*metabolism | 16 | 32.0 |
Fungal Proteins/metabolism | 2 | 1.0 |
Microtubule-Associated Proteins/metabolism | 18 | 12.0 |
Protein Kinase Inhibitors | 7 | 5.0 |
Protein p16 | 84 | 57.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Subcellular Fractions | 2 | 1.0 |
Pyrimidines/*chemical synthesis/chemistry/pharmacology | 2 | 9.0 |
G1 Phase/*immunology | 2 | 100.0 |
*Lymphocyte Activation | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
G0 Phase | 7 | 10.0 |
Lymphocyte Activation | 6 | 0.0 |
Carcinoma/*genetics | 3 | 2.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Drug Resistance, Neoplasm | 7 | 1.0 |
Cyclin-Dependent Kinases/*biosynthesis | 20 | 62.0 |
Cell Survival/drug effects | 9 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Cyclins/*biosynthesis | 13 | 25.0 |
Flavonoids/pharmacology | 3 | 0.0 |
Purines/pharmacology | 5 | 8.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Cyclin D1/genetics/*metabolism | 5 | 25.0 |
Gene Expression Regulation, Neoplastic/drug effects | 13 | 3.0 |
Genes, Reporter/genetics | 3 | 1.0 |
*Transcription Factors, TFII | 2 | 1.0 |
Sensitivity and Specificity | 4 | 0.0 |
Apoptosis/*drug effects/physiology | 4 | 3.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
Oncogene Proteins, Viral/genetics/metabolism | 3 | 25.0 |
Inhibitory Concentration 50 | 9 | 3.0 |
Retinoblastoma Protein/genetics/metabolism | 11 | 31.0 |
Catechin/*analogs & derivatives/pharmacology | 2 | 28.0 |
Cell Cycle Proteins/physiology | 4 | 10.0 |
Breast Neoplasms/pathology | 3 | 2.0 |
Cyclin A/genetics/metabolism | 2 | 28.0 |
Fenretinide/*pharmacology | 2 | 25.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 7 | 2.0 |
Tetracycline/pharmacology | 3 | 3.0 |
Administration, Oral | 2 | 0.0 |
Bone Neoplasms/*genetics | 2 | 4.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Cyclins/*genetics | 11 | 7.0 |
Papillomavirus, Human/genetics | 2 | 5.0 |
Adenoviridae/genetics/metabolism | 2 | 6.0 |
*Cell Division | 3 | 1.0 |
Cell Size | 2 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/genetics/metabolism | 4 | 80.0 |
Enzyme Induction | 3 | 0.0 |
Telomerase/*antagonists & inhibitors/metabolism | 2 | 66.0 |
*Gene Deletion | 21 | 2.0 |
Leukemia, Lymphocytic, Acute, L1/*genetics | 2 | 5.0 |
Rabbits | 4 | 0.0 |
*Cell Cycle | 25 | 11.0 |
Mitosis | 8 | 1.0 |
Binding, Competitive | 6 | 0.0 |
Biological Transport | 4 | 0.0 |
Carrier Proteins/*metabolism | 13 | 1.0 |
*Microtubule-Associated Proteins | 3 | 3.0 |
Neutralization Tests | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Sweden | 2 | 0.0 |
Cell Aging/*physiology | 5 | 9.0 |
*Fumonisins | 2 | 13.0 |
Protein Processing, Post-Translational/*drug effects | 2 | 3.0 |
Proto-Oncogene Proteins/*metabolism | 7 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Protein p16/metabolism | 17 | 29.0 |
Cyclin-Dependent Kinases/biosynthesis/metabolism | 2 | 50.0 |
Microtubule-Associated Proteins/biosynthesis | 2 | 11.0 |
*Protein Biosynthesis | 2 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis/metabolism | 3 | 60.0 |
Chromatography, Gel | 6 | 0.0 |
Lung Neoplasms | 2 | 1.0 |
Tretinoin/*metabolism/pharmacology | 2 | 11.0 |
Protein Kinases/*metabolism | 7 | 2.0 |
*Signal Transduction | 2 | 0.0 |
Carrier Proteins/*genetics/metabolism | 7 | 2.0 |
Glioblastoma/*genetics/metabolism | 3 | 25.0 |
Neoplasm Proteins/*genetics/metabolism | 3 | 2.0 |
Carrier Proteins/*genetics | 30 | 2.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Imidazoles/pharmacology | 3 | 1.0 |
Pyridines/pharmacology | 3 | 1.0 |
Camptothecin/*pharmacology | 2 | 5.0 |
Oncogene Proteins/metabolism | 5 | 6.0 |
Plasmids/metabolism | 5 | 0.0 |
*S Phase | 4 | 6.0 |
Chromosome Disorders | 2 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Arginine/genetics | 2 | 1.0 |
Cysteine/genetics | 2 | 1.0 |
Haplotypes | 3 | 0.0 |
Melanoma/epidemiology/*genetics | 3 | 20.0 |
Pancreatic Neoplasms/epidemiology/*genetics | 2 | 28.0 |
Skin Neoplasms/epidemiology/*genetics | 3 | 21.0 |
Statistics, Nonparametric | 3 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Cysteine Endopeptidases/*physiology | 2 | 6.0 |
Enzyme Inhibitors/*metabolism | 12 | 15.0 |
Multienzyme Complexes/*physiology | 2 | 10.0 |
Molecular Biology/methods | 2 | 7.0 |
Arsenicals/*pharmacology | 3 | 11.0 |
Oxides/*pharmacology | 3 | 13.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Telomerase/metabolism | 2 | 3.0 |
Antigens, Nuclear | 3 | 2.0 |
Predictive Value of Tests | 4 | 0.0 |
Proto-Oncogenes | 3 | 1.0 |
Transcription Factors/*genetics | 5 | 0.0 |
Genes, Tumor Suppressor/*genetics | 9 | 2.0 |
Glioma/*genetics | 8 | 10.0 |
Proteins/genetics | 5 | 0.0 |
RNA, Messenger/analysis | 15 | 0.0 |
Fibroblasts | 10 | 1.0 |
Rats, Wistar | 3 | 0.0 |
Oncogene Proteins, Viral/genetics/*metabolism | 2 | 6.0 |
Cell Cycle Proteins/analysis | 3 | 11.0 |
Genetic Diseases, Inborn/genetics | 2 | 4.0 |
Cyclin D1/*genetics | 5 | 8.0 |
Mice, Inbred C3H | 3 | 0.0 |
Nuclear Proteins/pharmacology | 2 | 22.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Threonine/*metabolism | 2 | 4.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Cyclin E/genetics/metabolism | 2 | 20.0 |
Microtubule-Associated Proteins/*metabolism | 16 | 15.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
*Genes, Tumor Suppressor | 20 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism | 2 | 7.0 |
Lung/metabolism | 4 | 2.0 |
Lung Neoplasms/*metabolism | 3 | 3.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 3 | 3.0 |
*Genes, myc | 3 | 1.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Receptors, Retinoic Acid/*metabolism | 2 | 3.0 |
Tretinoin/*pharmacology/therapeutic use | 2 | 14.0 |
Protein Kinases/metabolism | 9 | 2.0 |
Receptor, erbB-2/*physiology | 2 | 8.0 |
Risk Factors | 5 | 0.0 |
Retinoid X Receptors | 2 | 0.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Carcinogenicity Tests | 3 | 3.0 |
Carrier Proteins/genetics/*metabolism | 7 | 1.0 |
Tretinoin/pharmacology | 3 | 0.0 |
DNA Primers | 13 | 0.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Antineoplastic Agents/chemical synthesis/*pharmacology | 3 | 33.0 |
Chromosomes, Human, Pair 12 | 6 | 3.0 |
Calcium/metabolism | 4 | 0.0 |
RNA, Messenger/drug effects/metabolism | 3 | 2.0 |
Caspases/*metabolism | 3 | 1.0 |
*Gene Amplification | 15 | 3.0 |
*Oncogenes | 2 | 0.0 |
RNA, Messenger/biosynthesis | 9 | 0.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Cyclins/antagonists & inhibitors/metabolism | 3 | 100.0 |
Protein Binding/drug effects | 3 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/genetics/metabolism | 3 | 75.0 |
Amino Acid Substitution | 3 | 0.0 |
Cyclins/*pharmacology | 2 | 18.0 |
Interphase | 3 | 1.0 |
DNA, Complementary | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Retinoblastoma Protein/genetics/*metabolism | 7 | 15.0 |
Astrocytoma/*genetics | 4 | 8.0 |
Cell Cycle/*genetics | 11 | 14.0 |
Sequence Deletion | 10 | 0.0 |
Microfilament Proteins/*metabolism | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Clone Cells | 4 | 0.0 |
Cyclin D1/genetics/*physiology | 2 | 100.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Interleukin-6/*pharmacology | 5 | 2.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Astrocytoma/*genetics/*pathology | 2 | 40.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
S Phase/*physiology | 5 | 10.0 |
Breast Neoplasms/metabolism | 4 | 3.0 |
Keratinocytes | 2 | 5.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Retinoblastoma/metabolism | 2 | 28.0 |
Skin/metabolism | 2 | 1.0 |
Genes, cdc/physiology | 2 | 12.0 |
Lovastatin/*pharmacology | 3 | 13.0 |
Antigens, Neoplasm/*immunology | 3 | 1.0 |
Melanoma/*immunology | 4 | 4.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Histiocytoma, Fibrous/genetics/metabolism/*pathology | 2 | 66.0 |
Liposarcoma/genetics/metabolism/*pathology | 2 | 66.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Retroperitoneal Neoplasms/genetics/metabolism/*pathology | 2 | 100.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
Esophageal Neoplasms/*genetics | 3 | 4.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Cyclin D1/*biosynthesis | 7 | 35.0 |
Proto-Oncogene Proteins/*biosynthesis | 3 | 1.0 |
Cell Nucleus/enzymology | 3 | 3.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Cyclin A/metabolism | 11 | 14.0 |
Receptors, Calcitriol/genetics | 3 | 6.0 |
Cyclin-Dependent Kinases/*drug effects/metabolism | 3 | 60.0 |
Autoradiography | 2 | 0.0 |
Cyclin E/*biosynthesis | 2 | 25.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
Nuclear Proteins/*biosynthesis | 2 | 4.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 5 | 16.0 |
Retinoblastoma Protein/*biosynthesis | 2 | 20.0 |
Brain Neoplasms/*genetics/mortality | 2 | 40.0 |
Oncogenes/*genetics | 4 | 5.0 |
Alkaloids/*pharmacology | 4 | 7.0 |
Staurosporine/analogs & derivatives | 2 | 8.0 |
Carcinoma/*metabolism/pathology | 2 | 3.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Chromosomes, Human, Pair 9 | 8 | 4.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
*Trans-Activators | 3 | 0.0 |
Astrocytes/pathology | 2 | 5.0 |
Genes, Retinoblastoma/*genetics | 4 | 9.0 |
Microtubule-Associated Proteins/genetics/*metabolism | 3 | 7.0 |
Blood Proteins/pharmacology | 2 | 4.0 |
Skin/cytology | 2 | 1.0 |
Blood Physiology | 2 | 2.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
Saccharomyces cerevisiae | 5 | 1.0 |
DNA, Antisense/*genetics | 2 | 15.0 |
Leukemia, Promyelocytic, Acute/genetics | 2 | 16.0 |
Oncogene Proteins/biosynthesis/*genetics | 2 | 18.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 2 | 1.0 |
Acetylation/drug effects | 2 | 7.0 |
Antibiotics, Peptide/pharmacology | 2 | 7.0 |
Chromatin/*metabolism | 3 | 2.0 |
Histone Deacetylases/antagonists & inhibitors/*metabolism/*pharmacology | 2 | 100.0 |
Histones/genetics/metabolism | 2 | 15.0 |
*Peptides | 2 | 3.0 |
Staurosporine/pharmacology | 2 | 1.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 3 | 3.0 |
Cyclic AMP/pharmacology/*physiology | 2 | 50.0 |
Cyclic GMP/analogs & derivatives/pharmacology/*physiology | 2 | 50.0 |
Cyclin D1/antagonists & inhibitors/*physiology | 2 | 100.0 |
Muscle, Smooth, Vascular/*cytology/drug effects/metabolism | 2 | 28.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 6 | 8.0 |
Umbilical Arteries | 2 | 11.0 |
Mitosis/drug effects | 3 | 2.0 |
Pilot Projects | 2 | 0.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Glioma/*genetics/pathology | 2 | 6.0 |
Environmental Exposure | 2 | 1.0 |
Incidence | 2 | 0.0 |
Phosphothreonine/metabolism | 2 | 4.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Breast Neoplasms/*drug therapy/pathology | 2 | 5.0 |
Alternative Splicing | 3 | 0.0 |
*Ultraviolet Rays | 3 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Cyclin D1/*physiology | 2 | 28.0 |
Cyclin D1/*genetics/metabolism | 3 | 15.0 |
Flavonoids/*toxicity | 2 | 40.0 |
Half-Life | 2 | 0.0 |
Piperidines/*toxicity | 2 | 50.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
G1 Phase/*genetics | 4 | 19.0 |
Glutathione Transferase/genetics | 4 | 1.0 |
DNA Primers/genetics | 9 | 0.0 |
Adenoma/*genetics/pathology | 2 | 7.0 |
Mitotic Index | 4 | 2.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Simian virus 40 | 3 | 6.0 |
Retinoblastoma Protein/*genetics | 6 | 13.0 |
Microtubule-Associated Proteins/*biosynthesis | 2 | 9.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
DNA/genetics | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Genes, myc/*drug effects | 2 | 40.0 |
Mink | 6 | 9.0 |
Neoplasm Proteins/*antagonists & inhibitors | 2 | 15.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Oncogene Proteins/*genetics | 6 | 4.0 |
Prostatic Neoplasms/metabolism/*pathology | 4 | 5.0 |
Growth Substances/pharmacology | 2 | 1.0 |
PC12 Cells | 3 | 0.0 |
Epithelium/metabolism/pathology | 2 | 3.0 |
Keratinocytes/metabolism | 3 | 2.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Cyclin A/biosynthesis | 3 | 21.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Cell Nucleus/chemistry | 4 | 2.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Variation (Genetics) | 3 | 0.0 |
Melanoma/*metabolism | 3 | 4.0 |
*cdc25 Phosphatase | 2 | 4.0 |
Prostate-Specific Antigen/*biosynthesis | 2 | 20.0 |
Flavonoids/*pharmacology | 4 | 5.0 |
Piperidines/*pharmacology | 4 | 7.0 |
Cyclins/genetics/metabolism/*physiology | 2 | 28.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Cyclin E/biosynthesis | 2 | 25.0 |
Cyclin-Dependent Kinases/biosynthesis/*metabolism | 3 | 75.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis/*metabolism | 2 | 28.0 |
Transcription Factors/biosynthesis | 4 | 4.0 |
G1 Phase/drug effects/*physiology | 2 | 50.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Molecular Weight | 6 | 0.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
Histones/metabolism | 6 | 2.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Serine/metabolism | 6 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Exons/genetics | 3 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Retrospective Studies | 5 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Cyclin D1/biosynthesis/physiology | 2 | 100.0 |
Osteosarcoma/*metabolism/*pathology | 2 | 50.0 |
Retinoblastoma Protein/genetics | 4 | 10.0 |
Paraffin Embedding | 2 | 0.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
DNA, Neoplasm/metabolism | 5 | 3.0 |
Cyclin E/*physiology | 2 | 28.0 |
Chemical Fractionation | 2 | 2.0 |
Cyclin-Dependent Kinases/*genetics/*metabolism | 3 | 60.0 |
DNA, Neoplasm/analysis/genetics | 3 | 3.0 |
Neurons/*cytology | 3 | 5.0 |
CDC2 Protein Kinase/*metabolism | 4 | 3.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Glutathione Transferase | 3 | 7.0 |
CDC2 Protein Kinase/genetics/*metabolism | 2 | 12.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Carrier Proteins/*chemistry/metabolism | 2 | 5.0 |
Crystallization | 2 | 0.0 |
Enzyme Inhibitors/chemistry | 2 | 11.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Protein Structure, Secondary | 6 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Genes, Retinoblastoma/genetics | 2 | 6.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*physiology | 2 | 1.0 |
Melanoma/*metabolism/pathology | 2 | 5.0 |
Protein p16/*biosynthesis/genetics | 2 | 33.0 |
Receptors, Platelet-Derived Growth Factor/genetics | 2 | 13.0 |
Recurrence | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism | 5 | 15.0 |
Fibroblasts/cytology/metabolism | 3 | 1.0 |
Infant, Newborn | 7 | 0.0 |
Osteosarcoma/genetics/pathology | 2 | 33.0 |
Chromosome Mapping | 22 | 0.0 |
Androstadienes/pharmacology | 2 | 0.0 |
CDC2 Protein Kinase/genetics/metabolism | 2 | 13.0 |
Escherichia coli/genetics | 2 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/*metabolism | 4 | 30.0 |
Calcium/pharmacology | 2 | 0.0 |
Carrier Proteins/*biosynthesis/genetics | 3 | 5.0 |
Cyclin-Dependent Kinases/biosynthesis/*genetics | 4 | 100.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Mutagenesis, Site-Directed | 15 | 0.0 |
Heat-Shock Proteins 90/*antagonists & inhibitors | 2 | 16.0 |
Proteins | 2 | 3.0 |
Ploidies | 2 | 0.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Purines/*pharmacology | 2 | 11.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Caco-2 Cells | 2 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Neoplasm Proteins/*immunology | 2 | 5.0 |
T-Lymphocytes, Cytotoxic/*immunology | 6 | 1.0 |
cdc25 Phosphatase | 2 | 4.0 |
Cyclin D1/physiology | 2 | 40.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Down-Regulation/physiology | 2 | 2.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Transfection/genetics | 2 | 1.0 |
Brain Neoplasms/*genetics/metabolism | 2 | 7.0 |
Cyclin-Dependent Kinases/analysis/*genetics | 4 | 100.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Ankyrin Repeat | 2 | 15.0 |
*Protein Conformation | 3 | 1.0 |
Catalysis | 4 | 0.0 |
Escherichia coli | 7 | 1.0 |
Insects | 3 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Cyclins/*analysis | 5 | 12.0 |
Melanocytes/metabolism/*pathology | 2 | 33.0 |
Nuclear Proteins/biosynthesis | 2 | 4.0 |
S Phase/*drug effects | 3 | 16.0 |
*Alternative Splicing | 3 | 0.0 |
Feedback | 2 | 1.0 |
Mice, Inbred A | 2 | 3.0 |
Liposarcoma/*genetics | 2 | 33.0 |
Melanoma/genetics | 3 | 8.0 |
S Phase/drug effects/immunology | 2 | 100.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Recombinant Proteins | 3 | 0.0 |
Nuclear Proteins/*metabolism | 5 | 0.0 |
Estrogen Antagonists/pharmacology | 3 | 3.0 |
Breast Neoplasms/enzymology/*metabolism | 2 | 16.0 |
Epithelial Cells | 7 | 1.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Protein Binding/physiology | 2 | 0.0 |
Microtubule-Associated Proteins/*physiology | 3 | 13.0 |
Acetamides/*pharmacology | 2 | 16.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Lung Neoplasms/*genetics/pathology | 3 | 3.0 |
Antigens, Neoplasm/chemistry/genetics/*immunology | 2 | 40.0 |
Hamsters | 5 | 0.0 |
RNA Splicing | 2 | 0.0 |
Brain Neoplasms/*genetics/*pathology | 2 | 16.0 |
*Chromosomes, Human, Pair 9 | 3 | 1.0 |
Glioblastoma/*genetics/*pathology | 2 | 28.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Carrier Proteins/physiology | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 2 | 2.0 |
Cyclin D1/analysis/metabolism | 2 | 66.0 |
Cyclins/analysis/metabolism | 3 | 50.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Prostatic Neoplasms/*drug therapy/metabolism/pathology | 2 | 20.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Models, Chemical | 2 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Cell Cycle Proteins/*physiology | 4 | 7.0 |
Cyclin-Dependent Kinases/analysis/metabolism | 2 | 33.0 |
Retinoids/*pharmacology | 2 | 3.0 |
Endothelium, Vascular/cytology/*drug effects | 2 | 2.0 |
G0 Phase/*drug effects | 4 | 66.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 2 | 5.0 |
*DNA Replication | 3 | 1.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Tissue Distribution | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Melanoma | 2 | 2.0 |
Spodoptera/cytology | 2 | 4.0 |
Burkitt Lymphoma | 2 | 2.0 |
Cyclin D1/antagonists & inhibitors/metabolism | 2 | 100.0 |
Transcription Factors/physiology | 3 | 1.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Cell Cycle/genetics/physiology | 2 | 13.0 |
Protein-Serine-Threonine Kinases/analysis/metabolism | 2 | 50.0 |
Codon/genetics | 2 | 0.0 |
Mammals | 4 | 1.0 |
Cyclin-Dependent Kinases/*biosynthesis/*genetics | 2 | 100.0 |
DNA Probes | 2 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Recombinant Proteins/biosynthesis/metabolism | 4 | 2.0 |
Genes, Dominant | 3 | 0.0 |
Protein Synthesis Inhibitors/*pharmacology | 2 | 6.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Proliferating Cell Nuclear Antigen/analysis | 2 | 0.0 |
Protein Binding/genetics | 2 | 0.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Retroviridae/genetics/metabolism | 2 | 14.0 |
Cyclin E/physiology | 2 | 20.0 |
Sarcoma/*genetics | 4 | 11.0 |
Biopsy | 2 | 0.0 |
Cyclin D1 | 47 | 35.0 |
Estradiol/analogs & derivatives/pharmacology | 2 | 6.0 |
Sequence Analysis | 2 | 0.0 |
Xenopus | 2 | 0.0 |
Cyclins/drug effects/genetics/metabolism | 2 | 33.0 |
Lod Score | 2 | 0.0 |
Chromosomes, Human, Pair 13 | 3 | 2.0 |
Carrier Proteins/*genetics/*metabolism | 2 | 2.0 |
Embryo/cytology | 3 | 4.0 |
Oncogene Proteins/genetics/metabolism | 4 | 12.0 |
*Protein Kinase Inhibitors | 14 | 22.0 |
Protein p53/genetics/*metabolism | 3 | 1.0 |
Oncogene Proteins/*physiology | 2 | 8.0 |
CCAAT-Enhancer-Binding Proteins | 3 | 1.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Fibroblasts/cytology | 3 | 1.0 |
Interphase/*physiology | 2 | 18.0 |
Microinjections | 2 | 0.0 |
Cosmids | 2 | 0.0 |
Neoplasms/*genetics | 6 | 2.0 |
Cell Cycle Proteins/*genetics/metabolism | 2 | 3.0 |
Breast/*cytology | 2 | 5.0 |
Drug Resistance | 3 | 0.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Mitosis/*drug effects | 2 | 4.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
*Drosophila Proteins | 3 | 0.0 |
*Molecular Chaperones | 2 | 1.0 |
Oncogene Proteins/*biosynthesis | 4 | 23.0 |
T-Lymphocytes | 2 | 0.0 |
Cyclins/biosynthesis/*metabolism | 3 | 50.0 |
Epithelium/enzymology | 2 | 5.0 |
Prostatic Neoplasms | 2 | 3.0 |
Testis/metabolism | 2 | 0.0 |
Cell Lineage | 2 | 0.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Swine | 2 | 0.0 |
Cell Cycle Proteins/chemistry/*genetics/metabolism | 2 | 33.0 |
DNA Repair/genetics | 2 | 1.0 |
HT29 Cells/drug effects | 2 | 28.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Cyclins/genetics/*physiology | 2 | 20.0 |
Cyclin-Dependent Kinases/isolation & purification/metabolism | 2 | 50.0 |
DNA Probes/genetics | 2 | 1.0 |
Gene Amplification/*genetics | 5 | 4.0 |
Oncogene Proteins/genetics/*metabolism | 4 | 8.0 |
*Transformation, Genetic | 2 | 8.0 |
Consensus Sequence | 4 | 0.0 |
Protamine Kinase/metabolism | 5 | 21.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Leukemia, Pre-B-Cell/*genetics | 2 | 15.0 |
Astrocytoma/genetics | 5 | 20.0 |
Enzyme Stability | 2 | 1.0 |
Quinones/*pharmacology | 2 | 6.0 |
Cytochrome P-450 CYP2D6/genetics | 2 | 6.0 |
Epidermal Growth Factor/genetics | 2 | 2.0 |
Penetrance | 2 | 1.0 |
HT29 Cells | 2 | 1.0 |
Protein p53/biosynthesis/genetics | 3 | 6.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
Osteosarcoma | 2 | 2.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Ependymoma/genetics | 2 | 22.0 |
Oligodendroglioma/genetics | 2 | 25.0 |
G2 Phase | 2 | 1.0 |
Lymphocytes | 2 | 1.0 |
Neoplasms/*metabolism | 3 | 3.0 |
Molecular Structure | 7 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
Protein Kinase C/*physiology | 2 | 2.0 |
Cyclins/*biosynthesis/metabolism | 2 | 25.0 |
G1 Phase/*radiation effects | 2 | 40.0 |
S Phase/*radiation effects | 2 | 66.0 |
Cell Division/*physiology | 3 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Dogs | 3 | 0.0 |
Lung | 2 | 2.0 |
Chromosome Banding | 2 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Carrier Proteins/biosynthesis/chemistry/*metabolism | 3 | 17.0 |
Estrogen Antagonists/*pharmacology | 2 | 2.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
Tumor Cells, Cultured/cytology/drug effects/enzymology | 2 | 12.0 |
Chromones/pharmacology | 2 | 0.0 |
Morpholines/pharmacology | 2 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
RNA, Messenger/analysis/metabolism | 3 | 2.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 2 | 1.0 |
Neoplasm Metastasis | 2 | 0.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Adenocarcinoma | 2 | 1.0 |
Drug Synergism | 2 | 0.0 |
Neuroectodermal Tumors, Primitive/*genetics | 2 | 40.0 |
Protein Kinases/*analysis | 2 | 28.0 |
Cross Reactions | 2 | 0.0 |
DNA | 2 | 0.0 |
Proliferating Cell Nuclear Antigen | 4 | 1.0 |
*Phytotherapy | 3 | 3.0 |
Plant Roots/chemistry | 2 | 20.0 |
Cell Movement | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Heat-Shock Proteins 90/*metabolism | 2 | 8.0 |
Luciferases/metabolism | 3 | 0.0 |
U937 Cells | 2 | 0.0 |
Adenosine Triphosphate/chemistry | 2 | 8.0 |
Oncogene Proteins/*chemistry | 2 | 40.0 |
G1 Phase/genetics | 2 | 6.0 |
Cyclins/drug effects | 3 | 100.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Cell Line, Tumor/drug effects | 2 | 8.0 |
Protein p53/analysis | 3 | 1.0 |
Retinoblastoma Protein/metabolism/*physiology | 2 | 100.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Carcinoma/*pathology | 2 | 3.0 |
Tumor Suppressor Proteins/genetics/metabolism | 3 | 9.0 |
Cell Cycle Proteins/*biosynthesis/genetics | 2 | 12.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
*Movement Disorders | 2 | 16.0 |
*Parkinson Disease | 2 | 15.0 |
Thioredoxin Reductase (NADPH)/metabolism | 2 | 18.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Pyrimidines/chemical synthesis/*pharmacology | 2 | 40.0 |
Tumor Suppressor Proteins/genetics/*metabolism | 2 | 3.0 |
Blotting, Western/methods | 2 | 1.0 |
Carcinoma, Renal Cell/*pathology | 2 | 12.0 |
Kidney Neoplasms/*pathology | 2 | 6.0 |
Carcinoma, Hepatocellular/metabolism/*pathology | 2 | 11.0 |
Flavonoids/chemistry/*pharmacology | 2 | 15.0 |
Colonic Neoplasms | 2 | 1.0 |
